![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
April 15, 2022
In an enormous undertaking, ECOG-ACRIN and the NCI have built the knowledge base and infrastructure for future precision medicine trials. The new Genomics Subcommittee is offering expertise moving forward.
December 22, 2021
The purpose of this new subcommittee, led by Kristen Spencer, DO, MPH, is to develop molecularly-informed concepts—particularly combination concepts
November 16, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
September 30, 2021
This phase 2 trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
May 28, 2021
Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present a wide range of research findings at the 2021 ASCO Annual Meeting
April 27, 2021
A Standing Main Member of ECOG-ACRIN since 2005
March 31, 2021
This phase III study, led by Drs. Patrick Forde and Anna Nowak, is evaluating durvalumab immunotherapy during and after standard chemotherapy versus chemotherapy alone
January 25, 2021
This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma
October 19, 2020
September 14, 2020
A second interim analysis of this international adjuvant study for HR+, HER2- early breast cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
June 10, 2020
This phase II study is exploring the potent FLT3 inhibitor gilteritinib
June 10, 2020
The new virtual meeting format, developed out of necessity, sparked interesting conversations